Who are Carbo, 5FU, Cetuximab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rybrevant, NERATINIB, PONATINIB HYDROCHLORIDE, REGORAFENIB, Inlyta, PAZOPANIB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carbo-5fu-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Carbo, 5FU, Cetuximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carbo, 5FU, Cetuximab (Carbo, 5FU, Cetuximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agents. Area: Oncology.

phase 2 Antineoplastic agents EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Carbo, 5FU, Cetuximab (Carbo, 5FU, Cetuximab) — Groupe Oncologie Radiotherapie Tete et Cou. Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carbo, 5FU, Cetuximab TARGET	Carbo, 5FU, Cetuximab	Groupe Oncologie Radiotherapie Tete et Cou	phase 2	Antineoplastic agents	EGFR
Rybrevant	AMIVANTAMAB	Johnson & Johnson	marketed		EGFR, MET	2021-01-01
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agents class)

Asan Medical Center · 1 drug in this class
Central European Cooperative Oncology Group · 1 drug in this class
Croatian Cooperative Group for Clinical Research in Oncology · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Groupe Oncologie Radiotherapie Tete et Cou · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pfizer · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carbo, 5FU, Cetuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/carbo-5fu-cetuximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab